Upload
ganesa
View
32
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Healthy People 2010 Focus Area 4: Chronic Kidney Disease Progress Review September 21, 2006. Status of Chronic Kidney Disease Objectives. 4-1. End-stage renal disease 4-2. Cardiovascular disease deaths in persons with chronic kidney failure - PowerPoint PPT Presentation
Citation preview
Healthy People 2010 Focus Area 4:
Chronic Kidney Disease
Progress ReviewSeptember 21, 2006
4-1. End-stage renal disease 4-2. Cardiovascular disease deaths in persons with chronic
kidney failure4-3. Counseling for chronic kidney failure care 4-4. Use of arteriovenous fistulas4-5. Registration for kidney transplantation4-6. Waiting time for kidney transplantation4-7. End-stage renal disease due to diabetes4-8a. Medical evaluation for persons with type 1 or type 2 diabetes and chronic kidney disease4-8b. Medical treatment for persons with type 1 or type 2 diabetes and chronic kidney disease
Status of Chronic Kidney Disease Objectives
Improving Getting worse
Baseline data onlyTarget met
End-stage Renal Disease, By Race/Hispanic Origin
Obj. 4-1Note: American Indian includes Alaska Native. Asian includes Pacific Islander. Persons of Hispanic origin may be any race. SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
Asian
Incidence rate per 1,000,000 population
1999 2000 2001 2002 2003
2010 Target
Total White
Black
Hispanic
American Indian
19981997 2004
1,200
1,000
800
600
400
200
0
End-stage Renal Disease Due to Diabetes,
By Race/Hispanic Origin
Obj. 4-7Note: American Indian includes Alaska Native. Asian includes Pacific Islander. Persons of Hispanic origin may be any race. SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
Asian
Incidence rate per 1,000,000 population
1999 2000 2001 2002 2003
2010 Target
Total White
Black
Hispanic
American Indian
19981997 2004
1,200
1,000
800
600
400
200
0
Asian
1999 2000 2001 2002 2003
TotalWhite
Black
Hispanic
American Indian
1998
1997 2004
1,200
1,000
800
600
400
0
ESRD and ESRD Due to Diabetes,By Race/Hispanic Origin
Incidence rate per million
1999 2000 2001 2002 20031998
1997 2004
1,200
1,000
800
600
400
200
0
Asian
2010 Target
Total
Black
Hispanic
American Indian
200White
Obj. 4-1
Note: American Indian includes Alaska Native. Asian includes Pacific Islander. Persons of Hispanic origin may be any race. SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
Obj. 4-7
End-stage Renal Disease End-stage Renal DiseaseDue to Diabetes
2010 Target
End-stage Renal Disease, By Race and Gender
Incidence rate per 1,000,000
Obj. 4-1Note: American Indian includes Alaska Native. Asian includes Pacific Islander. SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
Men
Women
Asian
American Indian
Black
White
Asian
American Indian
Black
White
1,2001,0008006004002000
1998-2000 2001-2003
2010 Target
End-stage Renal Disease, By Health Service Area, 1993Incidence rate per 1,000,000
population
Obj. 4-1SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
End-stage Renal Disease, By Health Service Area, 2003Incidence rate per 1,000,000
population
Obj. 4-1SOURCE: United States Renal Data System (USRDS), NIH, NIDDK.
Males
End-stage Renal Disease Due to Diabetes,
By GenderIncidence rate per 1,000,000 population
2010 Target
Total
Females
Obj. 4-7SOURCE:United States Renal Data System (USRDS), NIH, NIDDK.
1999 2000 2001 2002 200319981997 2004
200
180
160
140
120
100
80
60
40
20
0
Asian
Use of Arteriovenous Fistulas* Among the Newly Diagnosed
By Race/Hispanic OriginPercent
1999 2000 2001 2002 2003
2010 Target
Total
White
Black
Hispanic
American Indian
Obj. 4-4
Note: American Indian includes Alaska Native. Asian includes Pacific Islander. The categories black and white exclude persons of Hispanic origin. Persons of Hispanic origin may be any race. SOURCE: Centers for Medicare and Medicaid Services (CMS) Clinical Performace Measures (CPM) project.
1998
50
60
40
30
20
10
0
70
80
Females
Use of Arteriovenous Fistulas Among the Newly Diagnosed
By GenderPercent
1999 2000 2001 2002 2003
2010 Target
TotalMales
Obj. 4-4SOURCE: Centers for Medicare and Medicaid Services (CMS) Clinical Performance Measures (CPM) project.
1998
50
60
40
30
20
10
0
Percent
2010 Target
Obj. 4-8a
2000 2001 2002 2003 2004Note: American Indian includes Alaska Native; Native Hawaiian includes other Pacific Islander. Persons of Hispanic origin may be any race. Only one race category could be recorded. Recording more than one race was not an option.SOURCE: Centers for Medicare and Medicaid Services (CMS); United States Renal Data System (USRDS), NIH, NIDDK.
AsianWhite
Black
Hispanic
American Indian
50
60
40
30
20
10
0
Medical Evaluation for Persons with Diabetes and Chronic Kidney Disease
Percent
2010 Target
Obj. 4-8a
2000 2001 2002 2003 2004Note: American Indian includes Alaska Native; Native Hawaiian includes other Pacific Islander. Persons of Hispanic origin may be any race. Only one race category could be recorded. Recording more than one race was not an option.SOURCE: Centers for Medicare and Medicaid Services (CMS); United States Renal Data System (USRDS), NIH, NIDDK.
AsianWhite
Black
Hispanic
American Indian
50
60
40
30
20
10
0
Medical Evaluation for Persons with Diabetes and Chronic Kidney Disease
Medical evaluation include eye examinations, lipid testing, and glycosylated hemoglobin (HbA1c) testing
0Percent
2010Target
4020
Total
Hispanic
Asian
Obj. 4-8b
American Indian
Black
White
Native Hawaiian
Medical Treatment for Persons with Diabetes and Chronic Kidney Disease
Note: American Indian includes Alaska Native; Native Hawaiian includes other Pacific Islander. Persons of Hispanic origin may be any race. SOURCE: USRDS.
*
3010
*
*
*
2000
0Percent
2010Target
4020
Total
Hispanic
Asian
Obj. 4-8b
American Indian
Black
White
Native Hawaiian
Medical Treatment for Persons with Diabetes and Chronic Kidney Disease
Note: American Indian includes Alaska Native; Native Hawaiian includes other Pacific Islander. Persons of Hispanic origin may be any race. SOURCE: USRDS.
*
3010
*
*
*
Medical treatment includes the use of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB)200
0
Progress review data and slides
are available on the web at:
http://www.cdc.gov/nchs/hphome.htmhttp://www.cdc.gov/nchs/hphome.htm